Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Tech sector outlook
9th Mar 2026
Real Estate Credit Investments (RECI)
Manager presentation and Q&A
4th Mar 2026
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
130: How deeptech can insulate investors from AI software concerns | Ilian Iliev of EMV Capital
Stay up-to-date with the latest research
Sign up to our newsletter
Ranked at number 4 in FeedSpot Podcasts for '10 Best Venture Capital Podcasts UK Edition 2026' -
Leading podcast in EIS
Life Sciences research
Advanced Oncotherapy
Life Sciences
Major milestone achieved
By
Dr Martin Hall
29 Sep 2022
Tissue Regenix
Life Sciences
Operating leverage
By
Dr Martin Hall
27 Sep 2022
Stay up-to-date with the latest research
Sign up to our newsletter
Shield Therapeutics Plc
Life Sciences
Accrufer momentum building
By
Dr Martin Hall
15 Sep 2022
Shield Therapeutics Plc
Life Sciences
Looking to accelerate positive signals in the US
By
Dr Martin Hall
26 Jul 2022
Tissue Regenix
Life Sciences
Strong 1H’22 sales suggest upside potential
19 Jul 2022
Cizzle Biotechnology
Life Sciences
Considerable progress in first year since listing
By
Dr Martin Hall
11 Jul 2022
International Biotechnology Trust
Life Sciences
M&A activity on the rise
By
Dr Martin Hall
30 Jun 2022
Tissue Regenix
Life Sciences
On pathway to sustainability
By
Dr Martin Hall
19 Apr 2022
Cizzle Biotechnology
Life Sciences
April 2022 Monthly
By
Dr Martin Hall
01 Apr 2022
Advanced Oncotherapy
Life Sciences
LIGHT: regulatory update
By
Dr Martin Hall
14 Mar 2022
Shield Therapeutics Plc
Life Sciences
PBMs have bought in to Accrufer
By
Dr Martin Hall
02 Mar 2022
Prev
1
2
3
4
5
...
22
Next
